$PTCHF News

PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO

PureTech Health H2 Earnings Call Highlights

PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript

PureTech Announces Annual Results for Year Ended December 31, 2025

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

PureTech Health Notifies Nasdaq Of Intention To Delist ADSs, Maintains Primary Listing On London Stock Exchange

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

PureTech Health: Notice of Results

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers

PureTech Health Publishes Data From Phase 2b ELEVATE IPF Study Of Deupirfenidone To Treat Idiopathic Pulmonary Fibrosis

PureTech Health shares are trading higher. The company noted that its unit Seaport Therapeutics announced topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo and plans to advance the prodrug into two parallel trials.

PureTech's Founded Entity, Seaport Therapeutics, Announces Topline Data From Portions Of Ongoing Phase 1 Proof-Of-Concept Clinical Trial Evaluating GlyphAgo

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

PureTech Health's Seaport Therapeutics Announces Publication Of First-In-Human Clinical And Preclinical Data For GlyphAllo In Science Translational Medicine

PureTech to Present at the Leerink Partners Global Healthcare Conference

PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

PureTech Health Announces That The FDA And European Commission Have Granted Orphan Drug Designation To Deupirfenidone For The Treatment Of Idiopathic Pulmonary Fibrosis

PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript